Base de dados : LILACS
Pesquisa : D06.472.699.327.740.320.400 [Categoria DeCS]
Referências encontradas : 32 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 4 ir para página            

  1 / 32 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Id: biblio-1160779
Autor: Escobar, María Eugenia; Gryngarten, Mirta; Boulgourdjian, Elisabeth; Ropelato, Gabriela; Bergadá, César.
Título: Tema 2: endocrinología infantil. Acción terapéutica de los análogos del factor liberador de gonadotrofinas (LH-RH) en la pubertad precoz / Therapeutic action of analogues of gonadotropins releasing factor (LH-RH) in precocious puberty
Fonte: Bol. Acad. Nac. Med. B.Aires;(supl):317-21, jul. 1992.
Idioma: es.
Conferência: Apresentado em: Reunión Conjunta, 18. Sesión Científica, 2, Montevideo, 10-11 oct. 1996.
Descritores: Gonadotropinas
Hormônio Liberador de Gonadotropina/administração & dosagem
Puberdade Precoce/fisiopatologia
Puberdade Precoce/terapia
-Leuprolida/uso terapêutico
Pamoato de Triptorrelina/uso terapêutico
Limites: Masculino
Feminino
Responsável: AR1.1 - Biblioteca Rafael Herrera Vegas


  2 / 32 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-849349
Autor: Brasil. Ministério da Saúde.
Título: Protocolo clínico e diretrizes terapêuticas: endometriose / Clinical protocol and therapeutic guidelines: endometriosis.
Fonte: s.l; s.n; [2014].
Idioma: pt.
Descritores: Protocolos Clínicos/normas
Endometriose/diagnóstico
Endometriose/tratamento farmacológico
Endometriose/cirurgia
-Anticoncepcionais Orais/administração & dosagem
Danazol/administração & dosagem
Gosserrelina/administração & dosagem
Laparoscopia/métodos
Leuprolida/administração & dosagem
Progestinas/administração & dosagem
Pamoato de Triptorrelina/administração & dosagem
Limites: Humanos
Tipo de Publ: Revisão
Guia de Prática Clínica
Responsável: BR1.1 - BIREME


  3 / 32 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Borges, Maria de Fátima
Texto completo
Id: lil-767927
Autor: Borges, Maria de Fátima; Franciscon, Priscila de Melo; Cambraia, Thamy Contursi; Oliveira, Débora Matias; Ferreira, Beatriz Pires; Resende, Elisabete Aparecida Mantovani Rodrigues de; Palhares, Heloísa Marcelina Cunha.
Título: Evaluation of central precocious puberty treatment with GnRH analogue at the Triangulo Mineiro Federal University (UFTM)
Fonte: Arch. endocrinol. metab. (Online);59(6):515-522, Dec. 2015. tab.
Idioma: en.
Resumo: Objective To report our experience of treating central precocious puberty (CPP) with a GnRH analogue with respect to the final heights (FH) attained in patients who completed treatment. Subjects and methods Among 105 records of children diagnosed with precocious puberty, 62 cases (54 girls and 8 boys), who were treated with leuprolide acetate/3.75 mg/monthly, were selected, and divided into 4 groups: group 1 (G1), 25 girls who attained FH; group 2 (G2), 18 girls who completed treatment but did not reach FH; group 3 (G3), 11 girls still under treatment; and group 4 (G4), 8 boys, 5 of which attained FH. Treatment was concluded at a bone age of 12 years, and follow-up continued until FH was achieved. Results In both G1 and G2 groups, height standard deviation score (SDS), weight-SDS and percentile of body mass index (PBMI) did not show intra/intergroup differences at the beginning and at interruption of treatment, but when added, G1+G2, height-SDS and weight-SDS differed significantly (p = 0.002 and 0.0001, respectively). In G1, 19 of 25 cases attained TH, and average height gain was 16.7 cm (7.7- 27.1); there was significant difference between FH and prediction of FH at the start (PFH at start) (p = 0.0001), as well as between PFH at interruption vs TH and vs FH (p = 0.007) with FH higher than TH (p = 0.004). Significant correlation was identified between FH and height gain after treatment. Conclusion As shown by some studies, GnRH analogue treatment was effective in children with CPP reaching FH near the genetic target.
Descritores: Estatura/efeitos dos fármacos
Fármacos para a Fertilidade Feminina/uso terapêutico
Hormônio Liberador de Gonadotropina/análogos & derivados
Leuprolida/uso terapêutico
Puberdade Precoce/tratamento farmacológico
-Determinação da Idade pelo Esqueleto
Brasil
Estradiol/sangue
Seguimentos
Hormônio Foliculoestimulante Humano/sangue
Hormônio Luteinizante/sangue
Puberdade Precoce/sangue
Estudos Retrospectivos
Resultado do Tratamento
Testosterona/sangue
Limites: Criança
Pré-Escolar
Feminino
Humanos
Lactente
Masculino
Tipo de Publ: Estudo de Avaliação
Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  4 / 32 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: lil-706555
Autor: Gálvez S., Daniela; Schwarze M., Juan Enrique; Villa V., Sonia; Arguello B., Begoña; Pommer T., Ricardo.
Título: Uso de agonista de GnRH para inducir ovulación en ciclos de hiperestimulación ovárica controlada: experiencia de Clínica Monteblanco, Santiago, Chile / Use of GnRH agonist to induce ovulation cycles controlled ovarian hyperstimulation: experience of Monteblanco Clinic, Santiago, Chile
Fonte: Rev. chil. obstet. ginecol;79(1):27-30, 2014. tab.
Idioma: es.
Resumo: Objetivo: Presentar la experiencia de la Unidad de Medicina Reproductiva de Clínica Monteblanco con el uso de análogos GnRh para la inducción final de la maduración ovocitaria. Método: Se registraron los casos de IVF/ICSI durante el año 2012 en los que se indujo la maduración final ovocitaria con análogos GnRh (Lupron®). Todos los ciclos fueron estimulados con FSHr (Puregon®) y gonadotrofina urinaria altamente purificada (Menopur®), para la prevención del alza prematura de LH, el día 5° de estimulación se agregó diariamente antagonista de GnRh. La maduración ovocitaria final se realizó con 1,25 mg de acetato de leuprolide (Lupron®), posteriormente se realizó aspiración folicular bajo guía ecográfica. Todos los embriones obtenidos fueron vitrificados y transferidos en ciclos posteriores. Resultados: Entre enero y diciembre del año 2012 se registraron 110 pacientes cuya inducción de maduración final ovocitaria se realizó con acetato de leuprolide. El promedio de ovocitos recuperados fue de 21, la proporción de ovocitos maduros fue de 72 por ciento y la frecuencia de fecundación fue de 64 por ciento. No hubo ningún caso de síndrome de hiperestimulación ovárico severo. Conclusiones: En los casos presentados de inducción de la maduración ovocitaria final con acetato de leuprolida, los resultados obtenidos son óptimos en términos de número de ovocitos en metafase II recuperados y en frecuencia de fecundación, mostrando ser una alternativa eficiente en la prevención del síndrome de hiperestimulación ovárico severo, sin alterar el pronóstico de las pacientes.

Objective: To present the experience of the Reproductive Medicine Unit of Clinica Monteblanco inducing oocyte final maturation by GnRh analogue administration. Methods: We analysed all IVF/ICSI cases performed in 2012, in which final oocyte maturation was induced by administration of GnRH analogue (Lupron®). Controlled ovarian hyperstimulation was achieved bydaily rFSH (Puregon®) and highly purified urinary gonadotropin (Menopur®) administration. In order to prevent premature LH rise, on the 5th day of stimulation daily GnRH antagonist (Orgalutran®) was added. Final oocyte maturation was induced by the administration of 1.25 mg leuprolide acetate (Lupron®). Follicular aspiration was subsequently performed under ultrasound guidance. All embryos were vitrified and transferred in a subsequent cycle. Results: We registered 110 patients. The mean number of recovered oocytes was 21; the proportion of mature oocytes was 72 percent, and the fecundation rate reached was 64 percent. No case of severe ovarian hyperstimulation syndrome (OHSS) was recorded. Conclusions: In this cohort, the use of leuprolide acetate for induce final oocyte maturation demonstrated to be an efficient alternative to induce oocyte final maturation, while preventing OHSS.
Descritores: Fármacos para a Fertilidade Feminina/administração & dosagem
Hormônio Liberador de Gonadotropina/agonistas
Indução da Ovulação/métodos
Leuprolida/administração & dosagem
Síndrome de Hiperestimulação Ovariana
Limites: Humanos
Adulto
Feminino
Adulto Jovem
Responsável: CL1.1 - Biblioteca Central


  5 / 32 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-658264
Autor: Dante Corti O., Dante; Fonerón B., Andrónico; Troncoso S., Luis; Ebel S., Luis; Gil C., Gonzalo; Valdevenito A., Gonzalo; Vargas C., Ramiro; Osorio M., Francisco; Pereira, Nury.
Título: Eficacia de leuprolide 11, 25 mg para supresión de testosterona en pacientes con cáncer prostático / Leuprolide s efficacy 11, 25 mg for suppression of testosterone in patients with prostatic cancer
Fonte: Rev. chil. urol;76(2):83-86, 2011. tab, ilus.
Idioma: es.
Resumo: Introducción: Los agonistas LHRH son de elección en bloqueo androgénico por cáncer prostático. En base a pacientes castrados se considera un bloqueo adecuado una testosterona total plasmática < 50 ng/dl. Se ha sugerido controlar la testosterona total por la posibilidad de no lograr una supresión adecuada. Material y método: Entre junio de 2008 a marzo de 2009 se midió el nivel de testosterona total al tercer mes de administrada una dosis de leuprolide 11,25 mg IM. Los exámenes se realizaron en la mañana y en el mismo laboratorio. En un grupo de pacientes se estimó peso, talla e índice de masa corporal (IMC) y se evaluó su asociación con los niveles de testosterona alcanzados. Resultados: Se evaluaron 81 pacientes, la edad promedio fue 76,4 años. La testosterona total plasmática promedio fue 33,9 ng/dl. En 12/81 pacientes (14,8 por ciento) el nivel de testosterona fue menos 50 ng/dl. No se observó asociación entre la duración de hormonoterapia y los niveles de testosterona. En 40 pacientes se estimó peso, talla e IMC sin encontrarse asociación de estas variables con el nivel de testosterona. En los pacientes en que se aumentó la dosis a leuprolide 22,5 mg se obtuvo una adecuada supresión de testosterona. Conclusión: En los pacientes en tratamiento con agonistas LHRH se debe medir el nivel de testosterona plasmática dada la posibilidad de un bloqueo inadecuado. En pacientes en tratamiento con leuprolide 11,25 mg y testosterona menos 50 ng/dl el aumento de la dosis a 22,5 mg lograría un nivel de testosterona en rangos de castración quirúrgica.

Introduction: The agonistas are LHRH of election in blockage androgenic for prostatic cancer. On the basis of castrated patients considers an adequate blockage a total plasmatic testosterone < 50 ng/dl. The total testosterone for the possibility to not to achieve an adequate suppression has been suggested to control. Material and method: Between June 2008 to March 2009 leuprolide's dose measured the level of total testosterone itself to person under administration's third month 11.25 mg IM. The exams had done in the morning and at the same laboratory. Weight, size and index of muscle mass (IMC) were estimated in patients' group and his association with the levels of testosterone caught up with was evaluated. Results: We evaluated 81 patients, the mean age was 76.4 years. The total testosterone the average plasmatic was 33.9 ng/dl. In 12/81 patient (14.8 percent) the level of testosterone was > 50 ng/dl. we did not observe association between hormonoterapia's duration and the levels of testosterone. Weight, size and IMC without finding association of these variables with the level of testosterone were estimated in 40 patients. We got an adequate suppression from testosterone in the patients that 22.5 mg increased itself the dose in to leuprolide. Conclusion: LHRH must try on in the patients in treatment with agonistic the level of plasmatic testosterone once the possibility of an inadequate blockage was given. In patients in treatment with leuprolide 11.25 mg and testosterone > 50 ng/dl the increase of the dose to 22.5 mg would achieve a level of testosterone in ranges of surgical castration.
Descritores: Antineoplásicos Hormonais/administração & dosagem
Leuprolida/administração & dosagem
Neoplasias da Próstata/tratamento farmacológico
Testosterona/sangue
-Índice de Massa Corporal
Neoplasias da Próstata/sangue
Limites: Humanos
Masculino
Pessoa de Meia-Idade
Idoso de 80 Anos ou mais
Responsável: CL10.1 - Biblioteca Biomédica


  6 / 32 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-506647
Autor: Benetti-Pinto, Cristina Laguna; Camargo, Luciana Bandeira Nunes; Magna, Luis Alberto; Garmes, Heraldo Mendes; Petta, Carlos Alberto.
Título: Fatores determinantes do ganho na altura em meninas com puberdade precoce central idiopática tratadas com análogo de GnRH / Predictive factors for height gain in idiopathic central precocious puberty treated with GnRH analogues
Fonte: Rev. bras. ginecol. obstet;30(12):609-613, dez. 2008. graf, tab.
Idioma: pt.
Resumo: OBJETIVO: avaliar fatores determinantes de maior ganho na estatura como resultado do tratamento com GnRHa. MÉTODOS: estudo retrospectivo de 33 meninas com puberdade precoce central idiopática tratadas com GnRHa. Foram avaliadas: idade no início dos sintomas e no início do tratamento, tempo decorrido entre o início de aparecimento dos caracteres puberais e o início do tratamento, idade óssea, avanço da idade óssea, duração do tratamento com GnRHa, altura real e escore Z, altura predita e escore Z e dosagens hormonais de FSH e LH após estímulo com GnRH, que foram correlacionadas com o ganho de altura no final do tratamento, calculada pela diferença entre altura predita no final e início do tratamento. Para análise estatística foi utilizada a correlação linear de Pearson, além da regressão linear múltipla. RESULTADOS: a média de idade no início do tratamento foi 7,8±1,3 anos, com idade óssea média de 10,1±1,6 anos. O avanço da idade óssea era de 2,3±1,1 anos e foi controlado com o tratamento. O ganho em altura predita foi de 2,5±1,3 cm e foi correlacionado positivamente com o tempo decorrido entre o início dos sintomas e o início do tratamento e com o avanço da idade óssea, além de se correlacionar negativamente com o escore Z da altura no início do tratamento e com a altura predita no início do tratamento, sendo este último o principal fator determinante do ganho obtido com o tratamento. CONCLUSÕES: meninas com maior comprometimento da altura predita para a idade adulta, visualizado pelo maior desvio em relação à população (escore Z) e pelo maior avanço na idade óssea foram as que obtiveram maior benefício com o tratamento com GnRHa, não devendo ser excluídas do grupo a ser tratado.

PURPOSE: to evaluate predictive factors of response to GnRHa treatment in girls with idiopathic central precocious puberty. METHODS: a retrospective cohort study was conducted involving 33 girls diagnosed with idiopathic central precocious puberty and treated with GnRHa. The following independent variables were assessed: age at the beginning of therapy and at the onset of symptoms, time elapsed since the appearance of pubertal characteristics and the beginning of treatment, bone age, bone age advance, duration of GnRHa treatment, actual height and Z-score, predicted height and Z-score and hormone measurements of FSH and LH after GnRH stimulation, which were correlated with gain in height as a dependent variable at treatment discontinuation, calculated by the difference between the predicted height at the end and beginning of treatment. For statistical analysis, Pearson's linear correlation was used, in addition to multiple linear regression analysis. RESULTS: the mean age at the beginning of treatment was 7.8±1.3 years, with a mean bone age of 10.1±1.6 years. Bone age advance was 2.3±1.1 years and was controlled during the treatment period. Gain in predicted height was 2.5±1.3cm. It was positively correlated with time elapsed since the beginning of symptoms and the beginning of treatment and with bone age advance, while negatively correlated with the Z-score of height at the beginning of treatment and predicted height at the beginning of treatment, and the latter was the main factor determining gain from treatment. CONCLUSIONS: girls who had the most significant compromise of predicted adult height, as detected by a larger deviation from the population (Z-score) and the most considerable advance in bone age, received benefit from GnRHa therapy, and they must not be excluded from the group to be treated.
Descritores: Estatura
Hormônio Liberador de Gonadotropina/análogos & derivados
Leuprolida/uso terapêutico
Puberdade Precoce/tratamento farmacológico
Puberdade Precoce/fisiopatologia
-Estudos de Coortes
Prognóstico
Estudos Retrospectivos
Limites: Criança
Feminino
Humanos
Responsável: BR1.1 - BIREME


  7 / 32 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: lil-481310
Autor: Recabarren, Sergio E; Lobos, Alejandro; Figueroa, Yara; Padmanabhan, Vasantha; Foster, Douglas L; Sir-Petermann, Teresa.
Título: Prenatal testosterone treatment alters LH and testosterone responsiveness to GnRH agonist in male sheep
Fonte: Biol. Res;40(3):329-338, 2007. graf.
Idioma: en.
Projeto: Fondecyt.
Resumo: Although evidence is accumulating that prenatal testosterone (T) compromises reproductive function in the female, the effects of excess T in utero on the postnatal development of male reproductive function has not been studied. The aim of this study was to assess the influence of prenatal T excess on age-related changes in pituitary and gonadal responsiveness to GnRH in the male sheep. We used the GnRH agonist, leuprolide (10 µg/kg), as a pharmacologic challenge at 5, 10, 20 and 30 weeks of age. These time points correspond to early and late juvenile periods and the prepubertal and postpubertal periods of sexual development, respectively. LH and T were measured in blood samples collected before and after GnRH agonist administration. The area under the response curve (AUC) of LH increased progressively in both controls and prenatal T-treated males from 5 to 20 weeks of age (P<0.01). The LH responses in prenatal T-treated males were lower at 20 and 30 weeks of age compared to controls (P<0.05). AUC-T increased progressively in control males from 5 through 30 weeks of age and prenatal T-treated males from 5 to 20 weeks of age. The T response in prenatal T-treated males was higher at 20 weeks compared to controls of same age but similar to controls and prenatal T-treated males at 30 weeks of age (P <0.05). Our findings suggest that prenatal T treatment advances the developmental trajectory of gonadal responsiveness to GnRH in male offspring.
Descritores: Hormônio Liberador de Gonadotropina/agonistas
Gônadas/efeitos dos fármacos
Leuprolida/farmacologia
Hormônio Luteinizante/efeitos dos fármacos
Efeitos Tardios da Exposição Pré-Natal
Testosterona/farmacologia
-Área Sob a Curva
Hormônio Luteinizante/sangue
Ovinos
Fatores de Tempo
Testosterona/sangue
Limites: Animais
Feminino
Masculino
Gravidez
Responsável: BR1.1 - BIREME


  8 / 32 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-457808
Autor: Tognotti, Élvio; Cabar, Fábio Roberto; Tso, Leopoldo de Oliveira; Soares, Jonathas Borges; Busso, Newton Eduardo; Antunes Junior, Nélson.
Título: Uso de meia dose de agonista do GnRH de depósito para supressão hipofisária em ciclos de fertilização in vitro / Half-dose long-acting form of GnRH agonist for pituitary suppression in cycles of in vitro fertilization
Fonte: Rev. bras. ginecol. obstet;29(4):205-210, abr. 2007. tab.
Idioma: pt.
Resumo: OBJETIVO: descrever a experiência de um serviço de reprodução assistida com a utilização de meia dose de agonista do GnRH de depósito para a supressão hipofisária em ciclos de fertilização in vitro (FIV). MÉTODOS: estudo prospectivo em que foram avaliados ciclos de FIV ou "intracytoplasmatic sperm injection" (ICSI) utilizando meia dose de acetato de leuprolide de depósito, iniciado na fase lútea média do ciclo menstrual, no período de agosto de 2005 a março de 2006. Foi administrado FSH recombinante para indução ovariana controlada em dose variada. O hCG era administrado quando pelo menos um folículo atingisse 19 mm de diâmetro máximo. Realizou-se FIV ou ICSI nos oócitos maduros de acordo com fator de infertilidade. Transferiram-se até quatro embriões por paciente no segundo ou terceiro dia após a captação. O uso de progesterona foi iniciado no mesmo dia da coleta oocitária. A dosagem sérica de beta-hCG foi realizada no 14° dia após a coleta dos oócitos. Foram avaliados os seguintes parâmetros: número de ciclos aspirados, ciclos cancelados e ciclos transferidos, quantidade total de FSH utilizado, número de oócitos maduros, taxa de fertilização, número de embriões transferidos, taxa de implantação embrionária e taxa de gestação clínica. RESULTADOS: 109 ciclos de FIV/ICSI utilizaram o protocolo descrito. A média de idade das pacientes foi 34,9 anos. A taxa de cancelamento foi de 1,8 por cento dos ciclos iniciados. Foram utilizadas 1.905 UI de gonadotrofina, em média, por ciclo iniciado. Um total de 86,5 por cento dos oócitos obtidos eram maduros, e a taxa de fertilização foi de 76,3 por cento. A média de embriões transferidos foi 2,7. As taxas de gestação por aspiração e por transferência foram 25,2 e 25,7 por cento, respectivamente. Um total de 26,3 por cento das gestações eram gemelares e 5,3 por cento, trigemelares. CONCLUSÃO: a administração de meia dose (1,87 mg) de acetato de leuprolide de depósito para bloqueio hipofisário pode ser...

PURPOSE: to evaluate the experience of an assisted reproduction center that uses depot administration of half-dose of GnRH agonist for pituitary suppression in assisted reproductive cycles. METHODS: prospective study that evaluated in vitro fertilization or intracytoplasmatic sperm injection (IVF/ICSI) cycles utilizing half-dose of leuprolide acetate between August 2005 and March 2006. Recombinant FSH was administered for controlled ovarian induction based on the protocol. hCG was administered when at least one follicle reached 19 mm in diameter. IVF or ICSI was performed according to infertility factor. Up to four embryos were transferred on the second or third day after oocyte retrieval. Progesterone supplementation was initiated on the same day of oocyte retrieval, and after 14 days beta-hCG was measured. The following parameters were evaluated: number of aspirated cycles, cancelled cycles, transferred cycles, total dose of FSH employed, number of mature oocytes retrieved, fertilization rate, number of transferred embryos, embryo implantation rate, and pregnancy rate. RESULTS: A hundred and nine IVF/ICSI cycles were initiated. The mean age of the patients was 34.9 years. We observed 1.8 percent of cancellation rate. The mean total dose of gonadotrophins employed was 1,905 IU per cycle. We obtained 86.5 percent of mature oocytes and the fertilization rate was 76.3 percent. The mean number of embryos transferred was 2.7. Pregnancy rates per aspiration and per transfer were 25.2 and 25.7 percent, respectively. Of those who reached pregnancy, 26.3 percent were twins and 5.3 percent were triplets. CONCLUSIONS: the half-dose of GnRH depot employed for pituitary suppression was a useful alternative for ovarian stimulation in IVF cycles because it is comfortable and practical for the patient, besides its low cost.
Descritores: Fertilização In Vitro
Hormônio Liberador de Gonadotropina
Infertilidade
Leuprolida/administração & dosagem
Técnicas de Reprodução Assistida
Limites: Humanos
Feminino
Responsável: BR26.1 - Biblioteca Central


  9 / 32 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: lil-434581
Autor: Mericq G., M Verónica; Youlton R., Ronald; Willshaw Z., M. Eugenia.
Título: Efectividad de la terapia con leuprolide acetato de depósito cada tres meses en pubertad precoz central / Effectiveness of Leuprolide acetate therapy every three months in central precocious puberty
Fonte: Rev. méd. Chile;134(7):821-826, jul. 2006. tab.
Idioma: es.
Resumo: Background: Precocious puberty may reduce final adult height, and affected children may suffer social and emotional problems. The efficacy of treatment with a long acting agonist analogue of the gonadotropin releasing hormone (aLHRH) has been well demonstrated. Aim: To evaluated the efficacy of a new formulation of aLHRH (leuprolide, Lupron ®) for the suppression of gonadotropin activation and clinical signs of puberty. Material and methods: Eleven children (ten females) with idiopathic central precocious puberty, with a mean chronological age of 7.5±1.8 years and a bone age of 9.7±1.8 years were recruited. Testicular volume in the male was 15 ml. In females, Tanner stage for breast development was between 2-4 and mean ovarian volume was 2.3±0.8 ml. They were treated during 18 months with aLHRH, 11.25 mg administered intramuscularly every three months. Results: Clinical, hormonal and ultrasonographic signs of puberty regressed in all patients. The degree of suppression of LH was 87.7±5.1% at the end of the 18 months. No significant changes in bone mineral content were observed during the treatment period. Conclusions: Leuprolide (aLHRH) 11.25 mg, injected every three months, is effective for the control of central precocious puberty and allows to reduce the number of yearly injections from 12 to 4.
Descritores: Desenvolvimento Ósseo/efeitos dos fármacos
Fármacos para a Fertilidade/administração & dosagem
Hormônio Liberador de Gonadotropina/metabolismo
Leuprolida/administração & dosagem
Hormônio Luteinizante/agonistas
Puberdade Precoce/tratamento farmacológico
-Determinação da Idade pelo Esqueleto
Estatura
Densidade Óssea/efeitos dos fármacos
Densidade Óssea/fisiologia
Desenvolvimento Ósseo/fisiologia
Mama/efeitos dos fármacos
Mama/crescimento & desenvolvimento
Injeções Intramusculares
Hormônio Luteinizante/sangue
Ovário/efeitos dos fármacos
Testículo/efeitos dos fármacos
Testosterona/sangue
Limites: Criança
Feminino
Humanos
Masculino
Tipo de Publ: Ensaio Clínico
Estudo Multicêntrico
Responsável: BR1.1 - BIREME


  10 / 32 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: lil-424727
Autor: Recabarren, Sergio e; Sir-Petermann, Teresa; Lobos, Alejandro; Codner, Ethel; Rojas-Garc¡a, Pedro P; Reyes, V¡ctor.
Título: Response to the gonadotropin releasing hormone agonist leuprolide in immature female sheep androgenized in utero
Fonte: Biol. Res;38(2/3):235-244, 2005. tab, graf.
Idioma: en.
Projeto: National Fund for Scientific and Technological Development Research.
Resumo: Similar to women with Polycystic Ovary Syndrome (PCOS), female sheep treated prenatally with testosterone (T-females) are hypergonadotropic, exhibit neuroendocrine defects, multifollicular ovarian morphology, hyperinsulinemia and cycle defects. Hypergonadotropism and multifollicular morphology may in part be due to developmentally regulated increase in pituitary responsiveness to GnRH and may culminate in increased ovarian estradiol production. In this study, we utilized a GnRH agonist, leuprolide, to determine the developmental impact of prenatal testosterone exposure on pituitary-gonadal function and to establish if prenatal exposure produces changes in the reproductive axis similar to those described for women with PCOS. Eight control and eight T-females were injected intravenously with 0.1 mg of leuprolide acetate per kilogram of body weight at 5, 10 and 20 weeks of age. Blood samples were collected by means of an indwelling jugular vein catheter at 0, 3, 6, 9, 12, 18, 24, 30, 36, 42 and 48 hours after leuprolide. Area under the curve (AUC) of LH response to leuprolide increased progressively between the three ages studied (P<0.05). AUC of LH in T-females was higher than in control females of the same age at 5 and 10 weeks of age (P<0.05), but similar at 20 weeks of age. AUC of estradiol response was lower at 10 but higher at 20 weeks of age in T-females compared to controls of the same age (P<0.05). Our findings suggest that prenatal T treatment alters the pituitary and ovarian responsiveness in a manner comparable to that observed in women with PCOS.
Descritores: Leuprolida/metabolismo
Leuprolida/uso terapêutico
Receptores LHRH/análise
Receptores LHRH/antagonistas & inibidores
-Chile/epidemiologia
Estradiol/análise
Estradiol/sangue
Exposição Materna
Ovinos
Síndrome do Ovário Policístico/induzido quimicamente
Síndrome do Ovário Policístico/metabolismo
Síndrome do Ovário Policístico/sangue
Testosterona/administração & dosagem
Testosterona/efeitos adversos
Limites: Animais
Feminino
Gravidez
Recém-Nascido
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: CL1.1 - Biblioteca Central



página 1 de 4 ir para página            
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde